Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 8, 2013, Pages 1001-1014

  Maldonado, Rafael ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Attention deficit hyperactivity disorder; Concerta ; Equasym XL ; Medikinet Retard ; Metadate CD ; Methylphenidate; Pharmacokinetics; Ritalin LA

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ANOREXIA; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED RELEASE FORMULATION; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SLEEP DISORDER; SYMPTOMATOLOGY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DELAYED-ACTION PREPARATIONS; HUMANS; METHYLPHENIDATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84880351721     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.786041     Document Type: Review

References (61)

1. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005;90:2-7
2. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8
3. Swanson JM, Sergeant JA, Taylor E, et al. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 1998;351:429-33
4. Coghill D, Soutullo C, d'Aubuisson C, et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: Results from a European survey. Child Adolesc Psychiatry Ment Health 2008;2:31
5. Noe L, Hankin CS. Health outcomes of childhood attention-deficit/ hyperactivity disorder (ADHD): Health care use and work status of caregivers. Value Health 2001;4:142-3
6. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol 2007;32:711-27
7. Hakkaart-Van Roijen L, Zwirs BW, Bouwmans C, et al. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 2007;16:316-26
8. Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/ hyperactivity disorder. JAMA 2001;285:60-6
9. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines CADDRA. 2008. Available from: Http://www.caddra.ca [Last accessed 9 July 2012]
10. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder first upgrade. Eur Child Adolesc Psychait 2004;13(Suppl 1):17-30
11. National Institute for Health and Clinical Excellence (NICE): Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. NICE clinical guideline 72. 2008. Available from: Www.nice.org.uk/nicemedia/live/12061/42059/42059.pdf [Last accessed 9 July 2012]
12. Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother 2006;7:2119-39
13. Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: A review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry 2010;19:325-40
14. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004;14:11-28
15. Liu F, Muniz R, Minami H, Silva RR. Review and comparison of the long acting methylphenidate preparations. Psychiatr Q 2005;76:259-69
16. Patrick KS, González MA, Straughn AB, Markowitz JS. New methylphenidate formulations for the treatment of attention-deficit/ hyperactivity disorder. Expert Opin Drug Deliv 2005;2:121-43
17. Wigal SB, Gupta S, Heverin E, Starr HL. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attentiondeficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21:255-63
18. Parasrampuria DA, Schoedel KA, Schuller R, et al. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extendedrelease methylphenidate formulation in humans. J Clin Pharmacol 2007;47:1476-88
19. Modi NB, Wang B, Hu WT, Gupta SK. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm Drug Dispos 2000;21:23-31
20. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 2000;40:379-88
21. Rochdi M, González MA, Dirksen SJ. Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Int J Clin Pharmacol Ther 2004;42:285-92
22. Pentikis HS, Simmons RD, Benedict MF, Hatch SJ. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 2002;41:443-9
23. Wigal SB, Sanchez DY, DeCory HH, et al. Selection of the optimal dose ratio for a controlled-delivery formulation of methylphenidate. J Appl Res 2003;3:46-63
24. Fischer R, Schütz H, Grossmann M, et al. Bioequivalence of a methylphenidate hydrochloride extended-release preparation: Comparison of an intact capsule and an opened capsule sprinkled on applesauce. Int J Clin Pharmacol Ther 2006;44:135-41
25. Lee L, Kepple J, Wang Y, et al. Bioavailability of modified-release methylphenidate: Influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharm Drug Dispos 2003;24:233-43
26. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006;15:476-95
27. Concerta. Prescribing Information (November 2010). McNeil Pediatrics 28. Metadate CD+. Prescribing Information (September 2010). UCB, Inc. Available from: Www.fda.gov
28. Equasym XL. Summary of Product Characteristics (October 2011). Shire Pharmaceuticals
29. Medikinet XL 5 mg. Summary of Product Characteristics (December 2011). Flynn Pharma Ltd
30. Ritalin LA. Prescribing Information (June 2012). Novartis. Available from: Www.fda.gov
31. González MA, Pentikis HS, Anderl N, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002;40:175-84
32. Markowitz JS, Straughn AB, Patrick KS, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 2003;42:393-401
33. Haessler F, Tracik F, Dietrich H, et al. A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Int J Clin Pharmacol Ther 2008;46:466-76
34. Schütz H, Fischer R, Grossmann M, et al. Lack of bioequivalence between two methylphenidate extended modified-release formulations in healthy volunteers. Int J Clin Pharmacol Ther 2009;47:761-9
35. McDonagh MS, Peterson K, Thakurta S, et al. Drug class review: Pharmacologic treatments for attention deficit hyperactivity disorder: Final update 4 report [Internet]. Oregon Health & Science University, Portland (OR); 2011. Available from: Http://www.ncbi. nlm.nih.gov/books/NBK84419/[Last accessed 9 July 2012]
36. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 2001;108:883-92
37. Wigal SB, Wigal T, Schuck S, et al. Academic, behavioral, and cognitive effects of OROS- methylphenidate on older children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21:121-31
38. Heger S, Trott GE, Meusers M, et al. Switching from a short-acting to a long-acting methylphenidate preparation: A multicentre, open study in children with ADHD. [Article in German]. Z Kinder Jugendpsychiatr Psychother 2006;34:257-65
39. Lee SI, Hong SD, Kim SY, et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:210-16
40. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attentiondeficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009;29:239-47
41. Spencer TJ, Mick E, Surman CB, et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord 2011;15:286-94
42. Hoare P, Remschmidt H, Medori R, et al. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 2005;14:305-9
43. Wilens TE, Biederman J, Lerner M; Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attentiondeficit/hyperactivity disorder: Results from a one-year follow-up study. J Clin Psychopharmacol 2004;24:36-41
44. Wolff C, Alfred A, Lindermüller A, et al. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: Results of a 3-month noninterventional study. Curr Med Res Opin 2011;27(Suppl 2):35-44
45. Greenhill LL, Findling RL, Swanson JM; ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109:E39
46. Findling RL, Quinn D, Hatch SJ, et al. Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2006;15:450-9
47. Hirshey Dirksen SJ, D'Imperio JM, Birdsall D, Hatch SJ. A postmarketing clinical experience study of Metadate® CD. Curr Med Res Opin 2002;18:371-80
48. Sinzig JK, Dopfner M, Plück J, et al. Does a morning dose of methylphenidate retard reduce hyperkinetic symptoms in the afternoon? Z Kinder Jugendpsychiatr Psychother 2004;32:225-33
49. Sinzig JK, Dopfner M, Lehmkuhl G, et al. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:421-32
50. Dopfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):93-101
51. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003;5:833-41
52. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extendedrelease methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics 2004;113(3 Pt 1):e206-16
53. Sonuga-Barke EJ, Swanson JM, Coghill D, et al. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004;4:28
54. Sonuga-Barke EJ, Coghill D, Markowitz JS, et al. Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. J Am Acad Child Adolesc Psychiatry 2007;46:701-10
55. Dopfner M, Ose C, Fischer R, et al. Comparison of the efficacy of two different modified release methylphenidate preparation for the children and adolescents with attentiondeficit/hyperactivity disorder in a natural setting: Comparison of the efficacy of Medikinet ® Retard and Concerta ® - a randomized, controlled, double-blind multicenter clinical crossover trail. J Child Adolesc Pysychopharmacol 2011;21:445-54
56. Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 2003;5:545-55
57. Silva R, Muniz R, Pestreich LK, et al. Efficacy of two long acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 2005;15:637-54
58. Schulz E, Fleischhaker C, Hennighausen K, et al. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 2010;20:377-85
59. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: Epidemiology, prevention and management. CNS Drugs 2008;22:213-37
60. Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management. Wolraich M, Brown L, et al. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007-22
61. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):I7-30